



Clinical trial results:

A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Combined with Aluminum Hydroxide Adjuvant in Children, Toddlers, and Infants

Summary

EudraCT number	2014-000778-20
Trial protocol	FI Outside EU/EEA
Global end of trial date	20 June 2018

Results information

Result version number	v1 (current)
This version publication date	27 January 2019
First version publication date	27 January 2019

Trial information

Trial identification

Sponsor protocol code	NOR-202
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02153112
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Takeda Vaccine, Inc.
Sponsor organisation address	One Takeda Parkway, Deerfield, IL, United States, 60015
Public contact	Medical Director, Takeda, +1 8778253327, trialdisclosures@takeda.com
Scientific contact	Medical Director, Takeda, +1 8778253327, trialdisclosures@takeda.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001609-PIP01-14
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 June 2018
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	20 June 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the trial is to select the optimal formulation of the norovirus vaccine from different concentrations of virus-like particles (VLP) combined with aluminum hydroxide for further development in children.

Protection of trial subjects:

All study participants or their guardians were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 June 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Colombia: 349
Country: Number of subjects enrolled	Finland: 128
Country: Number of subjects enrolled	Panama: 363
Worldwide total number of subjects	840
EEA total number of subjects	128

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	480
Children (2-11 years)	360
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants took part in the study at 12 investigative sites in Finland, Panama, and Colombia from 23 June 2015 to 20 June 2018.

Pre-assignment

Screening details:

Healthy volunteers (children, toddlers and infants) were enrolled to receive either one, two or three doses of 4 formulation of norovirus GI.1/GII.4 bivalent virus like particle (VLP) vaccine.

Period 1

Period 1 title	Overall Study
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort 1, Group 1: 1 Dose

Arm description:

Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 1: 2 Doses
------------------	----------------------------

Arm description:

Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 2: 1 Dose
------------------	---------------------------

Arm description:

Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 2: 2 Doses
------------------	----------------------------

Arm description:

Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 2a: 1 Dose
------------------	----------------------------

Arm description:

Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 2a: 2 Doses
------------------	-----------------------------

Arm description:

Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 3: 1 Dose
------------------	---------------------------

Arm description:

Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 3: 2 Doses
------------------	----------------------------

Arm description:

Toddlers 6 months to <1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 2, Group 4: 2 Doses
------------------	----------------------------

Arm description:

Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine on Day 112.

Arm title	Cohort 2, Group 4: 3 Doses
------------------	----------------------------

Arm description:

Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide on Days 1, 56 and 112.

Number of subjects in period 1	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose
Started	61	59	61
Completed	57	57	58
Not completed	4	2	3
Consent withdrawn by subject	3	1	2
Adverse event, non-fatal	-	-	1
Lost to follow-up	1	1	-
Reason not Specified	-	-	-

Number of subjects in period 1	Cohort 1, Group 2: 2 Doses	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses
Started	59	60	60
Completed	57	57	58
Not completed	2	3	2
Consent withdrawn by subject	2	1	1
Adverse event, non-fatal	-	-	-
Lost to follow-up	-	2	1
Reason not Specified	-	-	-

Number of subjects in period 1	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses	Cohort 2, Group 4: 2 Doses
Started	60	60	180
Completed	52	58	165
Not completed	8	2	15
Consent withdrawn by subject	7	2	13

Adverse event, non-fatal	-	-	-
Lost to follow-up	1	-	1
Reason not Specified	-	-	1

Number of subjects in period 1	Cohort 2, Group 4: 3 Doses
Started	180
Completed	166
Not completed	14
Consent withdrawn by subject	12
Adverse event, non-fatal	-
Lost to follow-up	1
Reason not Specified	1

Period 2

Period 2 title	Intermediate Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort 1, Group 1: 1 Dose

Arm description:

Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 1: 2 Doses
------------------	----------------------------

Arm description:

Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.	
Arm title	Cohort 1, Group 2: 1 Dose
Arm description:	
Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.	
Arm title	Cohort 1, Group 2: 2 Doses
Arm description:	
Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.	
Arm title	Cohort 1, Group 2a: 1 Dose
Arm description:	
Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 2a: 2 Doses
------------------	-----------------------------

Arm description:

Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 3: 1 Dose
------------------	---------------------------

Arm description:

Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 3: 2 Doses
------------------	----------------------------

Arm description:

Toddlers 6 months to <1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 2, Group 4: 2 Doses
Arm description: Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine on Day 112.

Arm title	Cohort 2, Group 4: 3 Doses
Arm description: Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide on Days 1, 56 and 112.

Number of subjects in period 2	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose
Started	57	57	58
Completed	54	54	55
Not completed	3	3	3
Missing full vaccine regimen/primary endpoint data	3	3	3

Number of subjects in period 2	Cohort 1, Group 2: 2 Doses	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses
Started	57	57	58
Completed	57	52	56
Not completed	0	5	2
Missing full vaccine regimen/primary endpoint data	-	5	2

Number of subjects in period 2	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses	Cohort 2, Group 4: 2 Doses
Started	52	58	165

Completed	52	56	144
Not completed	0	2	21
Missing full vaccine regimen/primary endpoint data	-	2	21

Number of subjects in period 2	Cohort 2, Group 4: 3 Doses
Started	166
Completed	162
Not completed	4
Missing full vaccine regimen/primary endpoint data	4

Period 3

Period 3 title	Per-Protocol Period
Is this the baseline period?	Yes ^[1]
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort 1, Group 1: 1 Dose

Arm description:

Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 1: 2 Doses
------------------	----------------------------

Arm description:

Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 2: 1 Dose
Arm description:	
Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 2: 2 Doses
Arm description:	
Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 2a: 1 Dose
Arm description:	
Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 2a: 2 Doses
Arm description:	
Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 3: 1 Dose
Arm description:	
Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 1, Group 3: 2 Doses
Arm description:	
Toddlers 6 months to <1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine on Day 29.

Arm title	Cohort 2, Group 4: 2 Doses
Arm description:	
Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.	

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine on Day 112.

Arm title	Cohort 2, Group 4: 3 Doses
------------------	----------------------------

Arm description:

Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.

Arm type	Experimental
Investigational medicinal product name	Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide on Days 1, 56 and 112.

Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: Baseline characteristics were collected for the per-protocol set.

Number of subjects in period 3^[2]	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose
Started	54	54	55
Completed	54	54	55

Number of subjects in period 3^[2]	Cohort 1, Group 2: 2 Doses	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses
Started	57	52	56
Completed	57	52	56

Number of subjects in period 3^[2]	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses	Cohort 2, Group 4: 2 Doses
Started	52	56	144
Completed	52	56	144

Number of subjects in period 3^[2]	Cohort 2, Group 4: 3 Doses
Started	162

Completed	162
-----------	-----

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Baseline characteristics were collected for the per-protocol set.

Baseline characteristics

Reporting groups

Reporting group title	Cohort 1, Group 1: 1 Dose
Reporting group description: Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.	
Reporting group title	Cohort 1, Group 1: 2 Doses
Reporting group description: Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.	
Reporting group title	Cohort 1, Group 2: 1 Dose
Reporting group description: Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.	
Reporting group title	Cohort 1, Group 2: 2 Doses
Reporting group description: Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Reporting group title	Cohort 1, Group 2a: 1 Dose
Reporting group description: Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.	
Reporting group title	Cohort 1, Group 2a: 2 Doses
Reporting group description: Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Reporting group title	Cohort 1, Group 3: 1 Dose
Reporting group description: Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.	
Reporting group title	Cohort 1, Group 3: 2 Doses
Reporting group description: Toddlers 6 months to <1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Reporting group title	Cohort 2, Group 4: 2 Doses
Reporting group description: Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.	
Reporting group title	Cohort 2, Group 4: 3 Doses
Reporting group description: Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	

Reporting group values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose
Number of subjects	54	54	55
Age, Customized Units: Subjects			
Infants and Toddlers (28 days-23 months)	0	0	17
Children (2-11 years)	54	54	38
Age Continuous Units: years			
arithmetic mean	5.9	5.8	2.1
full range (min-max)	4 to 8	4 to 8	1 to 3
Sex: Female, Male Units: Subjects			
Female	32	24	27
Male	22	30	28
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	26	24	26
Not Hispanic or Latino	28	30	28
Not Reported	0	0	1
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	18	19	9
Asian	0	0	0
Black or African American	2	1	0
Native Hawaiian or Other Pacific Islanders	0	0	0
White	28	30	28
Multiracial	0	0	1
Other	6	4	17
Height Units: cm			
arithmetic mean	117.4	116.5	89.9
full range (min-max)	92 to 138	96 to 138	67 to 105
Weight Units: kg			
arithmetic mean	22.41	22.19	13.55
full range (min-max)	13.7 to 43.2	13.6 to 45.3	8.0 to 19.4

Reporting group values	Cohort 1, Group 2: 2 Doses	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses
Number of subjects	57	52	56
Age, Customized Units: Subjects			
Infants and Toddlers (28 days-23 months)	19	15	14
Children (2-11 years)	38	37	42

Age Continuous Units: years arithmetic mean full range (min-max)	2.1 1 to 3	1.9 1 to 3	2.1 1 to 3
Sex: Female, Male Units: Subjects			
Female Male	25 32	28 24	19 37
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino Not Hispanic or Latino Not Reported	29 27 1	52 0 0	56 0 0
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native Asian Black or African American Native Hawaiian or Other Pacific Islanders White Multiracial Other	9 0 0 0 27 1 20	11 0 8 0 0 0 33	10 0 10 0 2 0 34
Height Units: cm arithmetic mean full range (min-max)	89.8 73 to 104	89.7 74 to 117	89.9 72 to 110
Weight Units: kg arithmetic mean full range (min-max)	13.39 10.0 to 18.6	13.19 8.8 to 17.5	13.11 8.9 to 21.8

Reporting group values	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses	Cohort 2, Group 4: 2 Doses
Number of subjects	52	56	144
Age, Customized Units: Subjects			
Infants and Toddlers (28 days-23 months) Children (2-11 years)	52 0	56 0	144 0
Age Continuous Units: years arithmetic mean full range (min-max)	8.3 6 to 11	7.9 6 to 11	3.1 1 to 5
Sex: Female, Male Units: Subjects			
Female Male	24 28	27 29	77 67
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino Not Hispanic or Latino Not Reported	52 0 0	56 0 0	144 0 0

Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	24	29	69
Asian	1	0	0
Black or African American	7	5	16
Native Hawaiian or Other Pacific Islanders	1	0	0
White	2	0	1
Multiracial	0	0	0
Other	17	22	58
Height Units: cm			
arithmetic mean	70.6	69.3	60.2
full range (min-max)	63 to 80	64 to 75	50 to 71
Weight Units: kg			
arithmetic mean	9.02	8.85	6.33
full range (min-max)	6.0 to 14.0	6.2 to 11.1	3.5 to 9.5

Reporting group values	Cohort 2, Group 4: 3 Doses	Total	
Number of subjects	162	742	
Age, Customized Units: Subjects			
Infants and Toddlers (28 days-23 months)	162	479	
Children (2-11 years)	0	263	
Age Continuous Units: years			
arithmetic mean	3.0		
full range (min-max)	1 to 5	-	
Sex: Female, Male Units: Subjects			
Female	72	355	
Male	90	387	
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	162	627	
Not Hispanic or Latino	0	113	
Not Reported	0	2	
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	75	273	
Asian	0	1	
Black or African American	24	73	
Native Hawaiian or Other Pacific Islanders	0	1	
White	3	121	
Multiracial	0	2	
Other	60	271	
Height Units: cm			
arithmetic mean	60.2		

full range (min-max)	51 to 68	-	
Weight			
Units: kg			
arithmetic mean	6.35		
full range (min-max)	3.4 to 9.5	-	

End points

End points reporting groups

Reporting group title	Cohort 1, Group 1: 1 Dose
Reporting group description: Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.	
Reporting group title	Cohort 1, Group 1: 2 Doses
Reporting group description: Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.	
Reporting group title	Cohort 1, Group 2: 1 Dose
Reporting group description: Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.	
Reporting group title	Cohort 1, Group 2: 2 Doses
Reporting group description: Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Reporting group title	Cohort 1, Group 2a: 1 Dose
Reporting group description: Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.	
Reporting group title	Cohort 1, Group 2a: 2 Doses
Reporting group description: Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Reporting group title	Cohort 1, Group 3: 1 Dose
Reporting group description: Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.	
Reporting group title	Cohort 1, Group 3: 2 Doses
Reporting group description: Toddlers 6 months to <1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.	
Reporting group title	Cohort 2, Group 4: 2 Doses
Reporting group description: Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.	
Reporting group title	Cohort 2, Group 4: 3 Doses
Reporting group description: Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56, and 112.	

µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.

Reporting group title	Cohort 1, Group 1: 1 Dose
-----------------------	---------------------------

Reporting group description:

Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.

Reporting group title	Cohort 1, Group 1: 2 Doses
-----------------------	----------------------------

Reporting group description:

Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.

Reporting group title	Cohort 1, Group 2: 1 Dose
-----------------------	---------------------------

Reporting group description:

Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.

Reporting group title	Cohort 1, Group 2: 2 Doses
-----------------------	----------------------------

Reporting group description:

Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Reporting group title	Cohort 1, Group 2a: 1 Dose
-----------------------	----------------------------

Reporting group description:

Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.

Reporting group title	Cohort 1, Group 2a: 2 Doses
-----------------------	-----------------------------

Reporting group description:

Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Reporting group title	Cohort 1, Group 3: 1 Dose
-----------------------	---------------------------

Reporting group description:

Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.

Reporting group title	Cohort 1, Group 3: 2 Doses
-----------------------	----------------------------

Reporting group description:

Toddlers 6 months to <1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Reporting group title	Cohort 2, Group 4: 2 Doses
-----------------------	----------------------------

Reporting group description:

Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.

Reporting group title	Cohort 2, Group 4: 3 Doses
-----------------------	----------------------------

Reporting group description:

Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.

Reporting group title	Cohort 1, Group 1: 1 Dose
-----------------------	---------------------------

Reporting group description:

Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.

Reporting group title	Cohort 1, Group 1: 2 Doses
-----------------------	----------------------------

Reporting group description:

Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.

Reporting group title	Cohort 1, Group 2: 1 Dose
-----------------------	---------------------------

Reporting group description:

Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.

Reporting group title	Cohort 1, Group 2: 2 Doses
-----------------------	----------------------------

Reporting group description:

Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Reporting group title	Cohort 1, Group 2a: 1 Dose
-----------------------	----------------------------

Reporting group description:

Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.

Reporting group title	Cohort 1, Group 2a: 2 Doses
-----------------------	-----------------------------

Reporting group description:

Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Reporting group title	Cohort 1, Group 3: 1 Dose
-----------------------	---------------------------

Reporting group description:

Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.

Reporting group title	Cohort 1, Group 3: 2 Doses
-----------------------	----------------------------

Reporting group description:

Toddlers 6 months to <1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Reporting group title	Cohort 2, Group 4: 2 Doses
-----------------------	----------------------------

Reporting group description:

Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.

Reporting group title	Cohort 2, Group 4: 3 Doses
-----------------------	----------------------------

Reporting group description:

Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.

Primary: Percentage of Participants with a Seroresponse (Pan-Ig ELISA) in Cohort 1

End point title	Percentage of Participants with a Seroresponse (Pan-Ig ELISA) in Cohort 1 ^[1]
-----------------	--

End point description:

Seroresponse was defined as 4-fold rise or greater at Day 57 in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Primary
----------------	---------

End point timeframe:

Day 57

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	53	52	51	56
Units: percentage of participants				
number (confidence interval 95%)	77.4 (63.8 to 87.7)	63.5 (49.0 to 76.4)	74.5 (60.4 to 85.7)	85.7 (73.8 to 93.6)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	54	49	55
Units: percentage of participants				
number (confidence interval 95%)	53.2 (38.1 to 67.9)	70.4 (56.4 to 82.0)	71.4 (56.7 to 83.4)	92.7 (82.4 to 98.0)

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants with a Seroresponse (Pan-Ig ELISA) in Cohort 2

End point title	Percentage of Participants with a Seroresponse (Pan-Ig ELISA) in Cohort 2 ^[2]
-----------------	--

End point description:

Seroresponse was defined as 4-fold rise or greater at Day 140 in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Primary
----------------	---------

End point timeframe:

Day 140

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	131	146		
Units: percentage of participants				
number (confidence interval 95%)	57.3 (48.3 to 65.9)	84.9 (78.1 to 90.3)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 1

End point title	Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 1 ^[3]
-----------------	---

End point description:

Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 after either of the vaccination given on Days 1, 29, 56 or 112

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	61	59	61	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	52.5	66.1	34.4	45.8
Pain	52.5	66.1	34.4	35.6
Erythema	0	1.7	1.6	0
Induration	1.6	1.7	0	1.7
Swelling	0	5.1	0	0

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	60	60
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	26.7	30.0	11.7	13.3
Pain	26.7	25.0	8.3	13.3
Erythema	0	1.7	3.3	0
Induration	0	1.7	1.7	0
Swelling	0	1.7	0	0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	179		
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	22.2	30.7		
Pain	22.2	28.5		
Erythema	1.1	2.8		
Induration	0	0		
Swelling	0.6	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 2

End point title	Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 2 ^[4]
-----------------	---

End point description:

Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 after either of the vaccination given on Days 1, 29, 56 or 112

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	61	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	41.0	44.1	8.2	25.4
Pain	41.7	44.8	6.6	23.7
Erythema	0	0	3.3	5.1
Induration	0	0	0	1.7
Swelling	0	0	0	1.7

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	58	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	13.3	15.0	10.0	5.0
Pain	13.3	13.3	6.9	5.1
Erythema	0	0	1.7	0
Induration	0	1.7	0	0
Swelling	0	1.7	1.7	0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	178		
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	13.3	14.5		
Pain	13.6	14.6		
Erythema	0.6	0		
Induration	0	0		
Swelling	0.6	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 3

End point title	Percentage of Participants With Solicited Local (Injection Site)
-----------------	--

End point description:

Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type Primary

End point timeframe:

Day 3 after either of the vaccination given on Days 1, 29, 56 or 112

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	61	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	13.1	15.3	4.9	20.3
Pain	13.3	15.5	4.9	20.3
Erythema	0	0	1.6	3.4
Induration	0	0	1.6	0
Swelling	0	0	1.6	3.4

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	58	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	10.0	10.0	5.0	6.7
Pain	10.0	8.3	3.4	6.8
Erythema	0	0	0	0
Induration	0	1.7	0	0
Swelling	0	1.7	1.7	0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	178		
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	2.2	5.0		

Pain	2.3	5.1		
Erythema	0	0		
Induration	0	0		
Swelling	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 4

End point title	Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 4 ^[6]
-----------------	---

End point description:

Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Primary
----------------	---------

End point timeframe:

Day 4 after either of the vaccination given on Days 1, 29, 56 or 112

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	61	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	6.6	6.8	1.6	11.9
Pain	6.7	6.9	0	11.9
Erythema	0	0	1.6	0
Induration	0	0	1.6	1.7
Swelling	0	0	0	0

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	58	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	6.7	10.0	6.7	6.7
Pain	6.7	6.7	5.2	6.8

Erythema	0	0	0	0
Induration	0	1.7	1.7	0
Swelling	0	1.7	0	0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	178		
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	3.3	4.5		
Pain	3.4	4.5		
Erythema	0	0		
Induration	0	0		
Swelling	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 5

End point title	Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 5 ^[7]
-----------------	---

End point description:

Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Primary
----------------	---------

End point timeframe:

Day 5 after either of the vaccination given on Days 1, 29, 56 or 112

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not performed for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	61	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	0	5.1	1.6	5.1
Pain	0	5.2	0	5.1
Erythema	0	0	1.6	0

Induration	0	0	1.6	1.7
Swelling	0	0	0	0

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	58	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	3.3	1.7	3.3	8.3
Pain	3.3	1.7	3.4	8.5
Erythema	0	0	0	0
Induration	0	0	0	0
Swelling	0	0	0	0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	178		
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	1.7	2.8		
Pain	1.7	2.8		
Erythema	0	0		
Induration	0	0		
Swelling	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 6

End point title	Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 6 ^[8]
-----------------	---

End point description:

Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Primary
----------------	---------

End point timeframe:

Day 6 after either of the vaccination given on Days 1, 29, 56 or 112

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not performed for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	61	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	3.3	3.4	0	3.4
Pain	3.3	3.4	0	3.4
Erythema	0	0	0	0
Induration	0	0	0	1.7
Swelling	0	0	0	0

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	58	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	1.7	1.7	1.7	5.0
Pain	1.7	1.7	1.7	5.1
Erythema	0	0	0	0
Induration	0	0	0	1.7
Swelling	0	0	0	0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	179		
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	1.1	4.5		
Pain	0.6	4.5		
Erythema	0	0		
Induration	0	0		
Swelling	0	0		

Statistical analyses

Primary: Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 7

End point title	Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 7 ^[9]
-----------------	---

End point description:

Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Primary
----------------	---------

End point timeframe:

Day 7 after either of the vaccination given on Days 1, 29, 56 or 112

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	61	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	1.6	3.4	0	1.7
Pain	1.7	3.4	0	1.7
Erythema	0	0	0	0
Induration	0	0	0	0
Swelling	0	0	0	0

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	58	59
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	1.7	1.7	1.7	3.3
Pain	1.7	1.7	1.7	3.4
Erythema	0	0	0	0
Induration	0	0	0	0
Swelling	0	0	0	0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
------------------	----------------------------------	----------------------------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	178		
Units: percentage of participants				
number (not applicable)				
Any solicited local AEs	0.6	2.2		
Pain	0.6	2.2		
Erythema	0	0		
Induration	0	0		
Swelling	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Solicited Systemic Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination

End point title	Percentage of Participants With Solicited Systemic Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination ^[10]
-----------------	---

End point description:

Systemic AEs are defined as headache, fatigue, myalgia, arthralgia, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 4 to <9 years; and irritability/fussiness, drowsiness, loss of appetite, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 6 weeks to <4 years on the day of vaccination and daily through Day 7 after each vaccination. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).

End point type	Primary
----------------	---------

End point timeframe:

Days 1 through 7 after each vaccination given on Days 1, 29, 56 or 112

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	61	59	61	59
Units: percentage of participants				
number (not applicable)				
Any solicited systemic AEs	50.8	61.0	44.3	54.2
Headache	21.7	25.9	0	0
Fatigue	23.3	29.3	0	0
Myalgia	26.7	24.1	0	0
Arthralgia	1.7	6.9	0	0
Vomiting	8.3	5.2	6.6	6.8
Diarrhea	6.9	10.7	13.1	23.7
Irritability/Fussiness	0	0	23.0	30.5
Drowsiness	0	0	16.4	22.0
Loss of Appetite	0	0	21.3	33.9

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	60	60
Units: percentage of participants				
number (not applicable)				
Any solicited systemic AEs	41.7	43.3	56.7	50.0
Headache	0	0	0	0
Fatigue	0	0	0	0
Myalgia	0	0	0	0
Arthralgia	0	0	0	0
Vomiting	10.0	11.7	27.6	16.9
Diarrhea	18.3	18.3	31.0	25.4
Irritability/Fussiness	23.3	18.3	27.6	23.7
Drowsiness	23.3	21.7	22.4	20.3
Loss of Appetite	16.7	18.3	25.9	23.7

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	179		
Units: percentage of participants				
number (not applicable)				
Any solicited systemic AEs	60.0	59.2		
Headache	0	0		
Fatigue	0	0		
Myalgia	0	0		
Arthralgia	0	0		
Vomiting	21.6	23.6		
Diarrhea	31.8	30.9		
Irritability/Fussiness	40.3	41.6		
Drowsiness	33.5	33.1		
Loss of Appetite	22.7	19.7		

Statistical analyses

No statistical analyses for this end point

Primary: Body Temperature Through Day 7 Following Either Vaccination

End point title	Body Temperature Through Day 7 Following Either
-----------------	---

End point description:

Body temperature measurement was performed using the thermometer provided by the site through

Day 7 after each vaccination. The highest body temperature observed each day was recorded on the Diary Card. Body temperature is categorized as 1) Any (temperature 38°C or higher), 2) 38°C - <38.5°C, 3) 38.5°C - <39°C, 4) 39°C - <39.5°C, 5) 39.5°C - <40°C, 6) 40°C or higher. Number of participants with the particular body temperature is reported within the pre-defined categories. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).

End point type	Primary
----------------	---------

End point timeframe:

Post-vaccination approximately 30 minutes and 6 hours later, then daily through Day 7 after each vaccination given on Days 1, 29, 56 or 112

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	61	59	61	59
Units: participants				
Any (temperature 38°C or higher)	2	6	7	5
38°C - <38.5°C	0	2	2	3
38.5°C - <39°C	1	2	3	2
39°C - <39.5°C	1	2	1	0
39.5°C - <40°C	0	0	0	0
40°C or higher	0	0	1	0

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	60	60
Units: participants				
Any (temperature 38°C or higher)	6	8	8	11
38°C - <38.5°C	4	4	5	4
38.5°C - <39°C	1	3	3	2
39°C - <39.5°C	1	1	0	3
39.5°C - <40°C	0	0	0	2
40°C or higher	0	0	0	0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	179		
Units: participants				
Any (temperature 38°C or higher)	26	23		
38°C - <38.5°C	13	11		
38.5°C - <39°C	12	7		

39°C - <39.5°C	0	3		
39.5°C - <40°C	1	2		
40°C or higher	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With at Least One Unsolicited AE Following Either Vaccination Dose

End point title	Percentage of Participants With at Least One Unsolicited AE Following Either Vaccination Dose ^[12]
-----------------	---

End point description:

Unsolicited AEs are any local or systemic AEs, as defined by this study, that are not solicited. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).

End point type	Primary
----------------	---------

End point timeframe:

Unsolicited AEs were collected within 28 days of all vaccinations (Day 1 to 57 for Cohort 1 and Day 1 to 140 for Cohort 2)

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	61	59	61	59
Units: percentage of participants				
number (not applicable)	55.7	55.9	67.2	69.5

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	60	60
Units: percentage of participants				
number (not applicable)	55.0	46.7	73.3	70.0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	179		
Units: percentage of participants				

number (not applicable)	77.2	76.0		
-------------------------	------	------	--	--

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants with Serious Adverse Events (SAEs)

End point title	Percentage of Participants with Serious Adverse Events
-----------------	--

End point description:

A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).

End point type	Primary
----------------	---------

End point timeframe:

Cohort 1: Day 1 up to Day 210; Cohort 2: Day 1 up to Day 293

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not available for this endpoint.

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	61	59	61	59
Units: percentage of participants				
number (not applicable)	1.6	3.4	1.6	3.4

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	60	60
Units: percentage of participants				
number (not applicable)	10.0	1.7	10.0	8.3

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	179		
Units: percentage of participants				

number (not applicable)	9.4	13.4		
-------------------------	-----	------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with a Seroresponse for GI.1 Virus-Like Particle (VLP) (Pan-Ig ELISA)

End point title	Percentage of Participants with a Seroresponse for GI.1 Virus-Like Particle (VLP) (Pan-Ig ELISA)
End point description:	
Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Here, overall number of participants analyzed is the number of participants with data available at the given time point.	
End point type	Secondary
End point timeframe:	
Cohort 1: Day 57; Cohort 2: Day 140	

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	53	52	51	56
Units: percentage of participants				
number (confidence interval 95%)	88.7 (77.0 to 95.7)	82.7 (69.7 to 91.8)	92.2 (81.1 to 97.8)	92.9 (82.7 to 98.0)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	54	49	55
Units: percentage of participants				
number (confidence interval 95%)	78.7 (64.3 to 89.3)	94.4 (84.6 to 98.8)	95.9 (86.0 to 99.5)	100.0 (93.5 to 100.0)

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	138	150		

Units: percentage of participants				
number (confidence interval 95%)	94.9 (89.8 to 97.9)	98.0 (94.3 to 99.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with a Seroresponse for GII.4 Virus-Like Particle (VLP) (Pan-Ig ELISA)

End point title	Percentage of Participants with a Seroresponse for GII.4 Virus-Like Particle (VLP) (Pan-Ig ELISA)
End point description:	
Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.	
End point type	Secondary
End point timeframe:	
Cohort 1: Day 57; Cohort 2: Day 140	

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	53	52	51	56
Units: percentage of participants				
number (confidence interval 95%)	81.1 (68.0 to 90.6)	69.2 (54.9 to 81.3)	76.5 (62.5 to 87.2)	87.5 (75.9 to 94.8)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	54	49	55
Units: percentage of participants				
number (confidence interval 95%)	63.8 (48.5 to 77.3)	72.2 (58.4 to 83.5)	75.5 (61.1 to 86.7)	92.7 (82.4 to 98.0)

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	150		

Units: percentage of participants				
number (confidence interval 95%)	58.2 (49.4 to 66.7)	86.0 (79.4 to 91.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)

End point title	Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)
End point description: Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.	
End point type	Secondary
End point timeframe: Cohort 1: Day 57; Cohort 2: Day 140	

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	53	52	51	56
Units: titer				
geometric mean (confidence interval 95%)	6039.1 (4786.3 to 7619.9)	12907.6 (10875.5 to 15319.4)	2856.2 (2232.0 to 3654.9)	7350.8 (6208.6 to 8703.2)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	54	49	55
Units: titer				
geometric mean (confidence interval 95%)	3892.1 (2852.7 to 5310.3)	12623.8 (10074.0 to 15818.9)	1240.1 (948.3 to 1621.7)	7139.1 (5863.5 to 8692.2)

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	144	162		

Units: titer				
geometric mean (confidence interval 95%)	4121.1 (3688.4 to 4604.6)	11806.3 (10537.6 to 13227.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)

End point title	Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)
-----------------	--

End point description:

Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 57; Cohort 2: Day 140

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	53	52	51	56
Units: titer				
geometric mean (confidence interval 95%)	11057.9 (8257.3 to 14808.3)	10228.3 (8171.2 to 12803.3)	3293.0 (2220.5 to 4883.3)	7955.2 (6065.9 to 10433.0)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	54	49	55
Units: titer				
geometric mean (confidence interval 95%)	5950.6 (3927.2 to 9016.7)	10896.5 (8452.0 to 14048.0)	620.2 (383.7 to 1002.7)	3252.1 (2403.3 to 4400.7)

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
------------------	----------------------------------	----------------------------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	143	162		
Units: titer				
geometric mean (confidence interval 95%)	1316.2 (1103.9 to 1569.4)	3829.8 (3311.7 to 4428.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)

End point title	Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)
End point description: Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.	
End point type	Secondary
End point timeframe: Cohort 1: Day 57; Cohort 2: Day 140	

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	53	52	51	56
Units: ratio				
geometric mean (confidence interval 95%)	19.22 (12.98 to 28.44)	43.55 (25.21 to 75.25)	44.11 (28.48 to 68.32)	89.95 (56.51 to 143.18)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	54	49	55
Units: ratio				
geometric mean (confidence interval 95%)	13.01 (7.92 to 21.37)	43.99 (27.71 to 69.83)	47.45 (30.59 to 73.60)	276.41 (206.44 to 370.09)

End point values	Cohort 2, Group 4: 2	Cohort 2, Group 4: 3		
------------------	----------------------	----------------------	--	--

	Doses	Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	138	150		
Units: ratio				
geometric mean (confidence interval 95%)	34.11 (26.54 to 43.84)	122.80 (93.93 to 160.54)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)

End point title	Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)
-----------------	---

End point description:

Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 57; Cohort 2: Day 140

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	53	52	51	56
Units: ratio				
number (confidence interval 95%)	7.46 (5.63 to 9.87)	10.00 (6.74 to 14.85)	10.87 (7.48 to 15.77)	19.20 (12.66 to 29.11)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	54	49	55
Units: ratio				
number (confidence interval 95%)	5.62 (3.83 to 8.22)	11.93 (7.46 to 19.07)	9.54 (5.80 to 15.71)	55.73 (36.50 to 85.09)

End point values	Cohort 2, Group 4: 2	Cohort 2, Group 4: 3		
------------------	-------------------------	-------------------------	--	--

	Doses	Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	150		
Units: ratio				
number (confidence interval 95%)	7.85 (5.86 to 10.50)	23.55 (17.85 to 31.08)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP (HBGA)

End point title	Percentage of Participants with a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP (HBGA)
-----------------	---

End point description:

Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 57; Cohort 2: Day 140

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	47	44	49
Units: percentage of participants				
number (confidence interval 95%)	75.0 (60.4 to 86.4)	91.5 (79.6 to 97.6)	50.0 (34.6 to 65.4)	95.9 (86.0 to 99.5)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	47	30	41
Units: percentage of participants				
number (confidence interval 95%)	51.2 (35.5 to 66.7)	89.4 (76.9 to 96.5)	36.7 (19.9 to 56.1)	85.4 (70.8 to 94.4)

End point values	Cohort 2, Group 4: 2	Cohort 2, Group 4: 3		
------------------	-------------------------	-------------------------	--	--

	Doses	Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	129	144		
Units: percentage of participants				
number (confidence interval 95%)	48.1 (39.2 to 57.0)	67.4 (59.1 to 74.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)

End point title	Percentage of Participants with a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)
-----------------	---

End point description:

The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 57; Cohort 2: Day 140

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	52	50	49	53
Units: percentage of participants				
number (confidence interval 95%)	94.2 (84.1 to 98.8)	98.0 (89.4 to 99.9)	81.6 (68.0 to 91.2)	100.0 (93.3 to 100.0)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	50	40	50
Units: percentage of participants				
number (confidence interval 95%)	74.4 (58.8 to 86.5)	98.0 (89.4 to 99.9)	50.0 (33.8 to 66.2)	96.0 (86.3 to 99.5)

End point values	Cohort 2, Group 4: 2	Cohort 2, Group 4: 3		
------------------	-------------------------	-------------------------	--	--

	Doses	Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	137	157		
Units: percentage of participants				
number (confidence interval 95%)	92.0 (86.1 to 95.9)	94.9 (90.2 to 97.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)

End point title	Percentage of Participants with a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)
-----------------	--

End point description:

The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 57; Cohort 2: Day 140

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	48	45	49
Units: percentage of participants				
number (confidence interval 95%)	81.6 (68.0 to 91.2)	93.8 (82.8 to 98.7)	64.4 (48.8 to 78.1)	95.9 (86.0 to 99.5)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	51	38	46
Units: percentage of participants				
number (confidence interval 95%)	68.1 (52.9 to 80.9)	90.2 (78.6 to 96.7)	47.4 (31.0 to 64.2)	87.0 (73.7 to 95.1)

End point values	Cohort 2, Group 4: 2	Cohort 2, Group 4: 3		
------------------	-------------------------	-------------------------	--	--

	Doses	Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	147		
Units: percentage of participants				
number (confidence interval 95%)	48.5 (39.8 to 57.3)	70.7 (62.7 to 78.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)

End point title	Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)
-----------------	---

End point description:

Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 57; Cohort 2: Day 140

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	52	51	49	53
Units: titer				
geometric mean (confidence interval 95%)	166.4 (136.0 to 203.6)	491.4 (397.1 to 608.1)	135.2 (106.5 to 171.7)	346.0 (297.5 to 402.3)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	45	53	42	52
Units: titer				
geometric mean (confidence interval 95%)	145.0 (108.6 to 193.8)	531.1 (424.0 to 665.2)	63.1 (45.3 to 87.9)	350.1 (273.7 to 447.9)

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
------------------	----------------------------------	----------------------------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	142	162		
Units: titer				
geometric mean (confidence interval 95%)	202.2 (180.7 to 226.2)	561.7 (499.2 to 632.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA)

End point title	Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA)
-----------------	--

End point description:

Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 57; Cohort 2: Day 140

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50	49	46	51
Units: titer				
geometric mean (confidence interval 95%)	982.1 (652.4 to 1478.4)	933.6 (678.3 to 1284.9)	197.1 (119.0 to 326.5)	514.8 (372.1 to 712.3)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	54	43	51
Units: titer				
geometric mean (confidence interval 95%)	444.6 (261.9 to 754.8)	721.8 (510.2 to 1021.1)	68.5 (44.1 to 106.4)	282.6 (194.8 to 410.0)

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
------------------	----------------------------	----------------------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	150		
Units: titer				
geometric mean (confidence interval 95%)	102.4 (83.1 to 126.1)	243.9 (203.3 to 292.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)

End point title	Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)
End point description:	
Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.	
End point type	Secondary
End point timeframe:	
Cohort 1: Day 57; Cohort 2: Day 140	

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	52	50	49	53
Units: ratio				
geometric mean (confidence interval 95%)	8.93 (7.58 to 10.53)	23.07 (18.56 to 28.68)	7.22 (5.47 to 9.52)	22.15 (19.06 to 25.73)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	50	40	50
Units: ratio				
geometric mean (confidence interval 95%)	6.10 (4.41 to 8.42)	24.21 (19.36 to 30.29)	3.68 (2.64 to 5.13)	20.01 (15.54 to 25.76)

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
------------------	----------------------------	----------------------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	137	157		
Units: ratio				
geometric mean (confidence interval 95%)	11.48 (10.09 to 13.06)	32.03 (27.38 to 37.47)		

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)

End point title	Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)
-----------------	---

End point description:

Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level. Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 57; Cohort 2: Day 140

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	48	45	49
Units: ratio				
geometric mean (confidence interval 95%)	9.31 (6.93 to 12.52)	12.73 (9.60 to 16.90)	5.35 (3.94 to 7.28)	15.95 (12.31 to 20.66)

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	47	51	38	46
Units: ratio				
geometric mean (confidence interval 95%)	8.34 (5.01 to 13.87)	15.36 (11.26 to 20.96)	3.91 (2.60 to 5.88)	17.00 (11.66 to 24.80)

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
------------------	----------------------------------	----------------------------------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	147		
Units: ratio				
geometric mean (confidence interval 95%)	3.73 (2.84 to 4.90)	8.13 (6.39 to 10.35)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Any Adverse Event (AE) Leading to Withdrawal from the Study

End point title	Percentage of Participants with Any Adverse Event (AE) Leading to Withdrawal from the Study
-----------------	---

End point description:

Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participant is unwilling to continue because of the AE. Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 1 up to Day 210; Cohort 2: Day 1 up to Day 293

End point values	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose	Cohort 1, Group 2: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	61	59	61	59
Units: percentage of participants				
number (not applicable)	0	0	1.6	0

End point values	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	60	60
Units: percentage of participants				
number (not applicable)	0	0	0	0

End point values	Cohort 2, Group 4: 2 Doses	Cohort 2, Group 4: 3 Doses		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	179		
Units: percentage of participants				

number (not applicable)	0	0		
-------------------------	---	---	--	--

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Unsolicited AEs 28 days after each vaccination (Day 1 to 57 for Cohort 1 and Day 1 up to 140 for Cohort 2) and Serious Adverse Events (SAEs) throughout the trial (Up to Day 210 for Cohort 1 and Day 293 for Cohort 2)

Adverse event reporting additional description:

At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	Cohort 1, Group 1: 1 Dose
-----------------------	---------------------------

Reporting group description:

Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.

Reporting group title	Cohort 1, Group 1: 2 Doses
-----------------------	----------------------------

Reporting group description:

Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.

Reporting group title	Cohort 1, Group 2: 1 Dose
-----------------------	---------------------------

Reporting group description:

Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.

Reporting group title	Cohort 1, Group 2: 2 Doses
-----------------------	----------------------------

Reporting group description:

Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Reporting group title	Cohort 1, Group 2a: 1 Dose
-----------------------	----------------------------

Reporting group description:

Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.

Reporting group title	Cohort 1, Group 2a: 2 Doses
-----------------------	-----------------------------

Reporting group description:

Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Reporting group title	Cohort 1, Group 3: 1 Dose
-----------------------	---------------------------

Reporting group description:

Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.

Reporting group title	Cohort 1, Group 3: 2 Doses
-----------------------	----------------------------

Reporting group description:

Toddlers 6 months to <1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.

Reporting group title	Cohort 2, Group 4: 2 Doses
-----------------------	----------------------------

Reporting group description:

Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.

Reporting group title	Cohort 2, Group 4: 3 Doses
-----------------------	----------------------------

Reporting group description:

Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 µg/50 µg)/GI.1/GII.4 (50 µg/50 µg) or GI.1/GII.4 (50 µg/150 µg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.

Serious adverse events	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 61 (1.64%)	2 / 59 (3.39%)	1 / 61 (1.64%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Burns Third Degree			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Enteritis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated Inguinal Hernia			

subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Testicular Torsion			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthmatic Crisis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	1 / 61 (1.64%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue Fever			
subjects affected / exposed	0 / 61 (0.00%)	2 / 59 (3.39%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	1 / 61 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Furuncle			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical Pneumonia			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis Media Acute			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Viral			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			

subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup Infectious			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Bacterial			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle Abscess			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous Abscess			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Respiratory Syncytial Viral			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital Cellulitis			

subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Bacterial			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort 1, Group 2: 2 Doses	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 59 (3.39%)	6 / 60 (10.00%)	1 / 60 (1.67%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Burns Third Degree			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Enteritis			
subjects affected / exposed	1 / 59 (1.69%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated Inguinal Hernia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			

subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Testicular Torsion			
subjects affected / exposed	0 / 59 (0.00%)	1 / 60 (1.67%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthmatic Crisis			
subjects affected / exposed	0 / 59 (0.00%)	2 / 60 (3.33%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 60 (1.67%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue Fever			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Furuncle			

subjects affected / exposed	1 / 59 (1.69%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical Pneumonia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 60 (1.67%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis Media Acute			
subjects affected / exposed	0 / 59 (0.00%)	1 / 60 (1.67%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 59 (0.00%)	1 / 60 (1.67%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Viral			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup Infectious			

subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Bacterial			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle Abscess			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous Abscess			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Respiratory Syncytial Viral			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital Cellulitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Bacterial			

subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses	Cohort 2, Group 4: 2 Doses
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 60 (10.00%)	5 / 60 (8.33%)	17 / 180 (9.44%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Burns Third Degree			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 180 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 180 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Enteritis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated Inguinal Hernia			
subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Testicular Torsion			

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthmatic Crisis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 180 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	2 / 60 (3.33%)	2 / 60 (3.33%)	6 / 180 (3.33%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue Fever			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	2 / 180 (1.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Furuncle			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical Pneumonia			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Otitis Media Acute			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	2 / 60 (3.33%)	0 / 60 (0.00%)	2 / 180 (1.11%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Viral			
subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup Infectious			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 180 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Bacterial			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 180 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle Abscess			

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 180 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous Abscess			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 180 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Respiratory Syncytial Viral			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital Cellulitis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Bacterial			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort 2, Group 4: 3 Doses		
Total subjects affected by serious adverse events			
subjects affected / exposed	24 / 179 (13.41%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			

Injury, poisoning and procedural complications			
Burns Third Degree			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Enteritis			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incarcerated Inguinal Hernia			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intussusception			
subjects affected / exposed	1 / 179 (0.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Testicular Torsion			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthmatic Crisis			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asthma			

subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Pneumonia			
subjects affected / exposed	9 / 179 (5.03%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
Dengue Fever			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	1 / 179 (0.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Furuncle			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atypical Pneumonia			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Otitis Media Acute			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis			

subjects affected / exposed	4 / 179 (2.23%)			
occurrences causally related to treatment / all	0 / 5			
deaths causally related to treatment / all	0 / 0			
Tracheitis				
subjects affected / exposed	0 / 179 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis Viral				
subjects affected / exposed	0 / 179 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary Tract Infection				
subjects affected / exposed	4 / 179 (2.23%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Croup Infectious				
subjects affected / exposed	0 / 179 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis Bacterial				
subjects affected / exposed	1 / 179 (0.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Muscle Abscess				
subjects affected / exposed	0 / 179 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Subcutaneous Abscess				
subjects affected / exposed	2 / 179 (1.12%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pneumonia Respiratory Syncytial Viral				

subjects affected / exposed	2 / 179 (1.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
subjects affected / exposed	1 / 179 (0.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Encephalitis			
subjects affected / exposed	1 / 179 (0.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Periorbital Cellulitis			
subjects affected / exposed	1 / 179 (0.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia Bacterial			
subjects affected / exposed	1 / 179 (0.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cohort 1, Group 1: 1 Dose	Cohort 1, Group 1: 2 Doses	Cohort 1, Group 2: 1 Dose
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 61 (40.98%)	27 / 59 (45.76%)	28 / 61 (45.90%)
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 61 (3.28%)	5 / 59 (8.47%)	0 / 61 (0.00%)
occurrences (all)	2	5	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 61 (0.00%)	4 / 59 (6.78%)	4 / 61 (6.56%)
occurrences (all)	0	5	4
Blood and lymphatic system disorders			

Anaemia subjects affected / exposed occurrences (all)	0 / 61 (0.00%) 0	0 / 59 (0.00%) 0	0 / 61 (0.00%) 0
Gastrointestinal disorders			
Abdominal Pain Upper subjects affected / exposed occurrences (all)	3 / 61 (4.92%) 3	8 / 59 (13.56%) 8	0 / 61 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	0 / 61 (0.00%) 0	3 / 59 (5.08%) 4	3 / 61 (4.92%) 3
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal Pain subjects affected / exposed occurrences (all)	4 / 61 (6.56%) 4	0 / 59 (0.00%) 0	0 / 61 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	2 / 61 (3.28%) 3	5 / 59 (8.47%) 6	4 / 61 (6.56%) 4
Skin and subcutaneous tissue disorders			
Dermatitis Diaper subjects affected / exposed occurrences (all)	0 / 61 (0.00%) 0	0 / 59 (0.00%) 0	0 / 61 (0.00%) 0
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	15 / 61 (24.59%) 19	7 / 59 (11.86%) 7	5 / 61 (8.20%) 6
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	1 / 61 (1.64%) 1	4 / 59 (6.78%) 4	8 / 61 (13.11%) 12
Rhinitis subjects affected / exposed occurrences (all)	0 / 61 (0.00%) 0	0 / 59 (0.00%) 0	5 / 61 (8.20%) 6
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 61 (0.00%) 0	0 / 59 (0.00%) 0	4 / 61 (6.56%) 5
Otitis Media			

subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	4 / 61 (6.56%)
occurrences (all)	0	0	6
Gastroenteritis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	0	0	0
Viral Infection			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	0	0	0
Acarodermatitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	0	0	0
Pyoderma			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	0	0	0
Pharyngotonsillitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	0	0	0
Bronchiolitis			
subjects affected / exposed	0 / 61 (0.00%)	0 / 59 (0.00%)	0 / 61 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Cohort 1, Group 2: 2 Doses	Cohort 1, Group 2a: 1 Dose	Cohort 1, Group 2a: 2 Doses
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 59 (54.24%)	21 / 60 (35.00%)	19 / 60 (31.67%)
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	3 / 59 (5.08%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences (all)	3	0	0
Blood and lymphatic system disorders			

Anaemia subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0
Gastrointestinal disorders Abdominal Pain Upper subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	3 / 59 (5.08%) 4	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	5 / 59 (8.47%) 5	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0
Skin and subcutaneous tissue disorders Dermatitis Diaper subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	8 / 59 (13.56%) 10	14 / 60 (23.33%) 15	10 / 60 (16.67%) 12
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	7 / 59 (11.86%) 8	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	4 / 59 (6.78%) 4	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	2 / 59 (3.39%) 3	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0
Otitis Media			

subjects affected / exposed	5 / 59 (8.47%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences (all)	5	0	0
Gastroenteritis			
subjects affected / exposed	0 / 59 (0.00%)	5 / 60 (8.33%)	5 / 60 (8.33%)
occurrences (all)	0	5	6
Viral Infection			
subjects affected / exposed	0 / 59 (0.00%)	2 / 60 (3.33%)	1 / 60 (1.67%)
occurrences (all)	0	2	1
Pharyngitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	3 / 60 (5.00%)
occurrences (all)	0	0	3
Acarodermatitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences (all)	0	0	0
Pyoderma			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences (all)	0	0	0
Pharyngotonsillitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences (all)	0	0	0
Bronchiolitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Cohort 1, Group 3: 1 Dose	Cohort 1, Group 3: 2 Doses	Cohort 2, Group 4: 2 Doses
Total subjects affected by non-serious adverse events			
subjects affected / exposed	36 / 60 (60.00%)	35 / 60 (58.33%)	119 / 180 (66.11%)
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	6 / 180 (3.33%)
occurrences (all)	0	0	6
Blood and lymphatic system disorders			

Anaemia subjects affected / exposed occurrences (all)	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0	9 / 180 (5.00%) 9
Gastrointestinal disorders Abdominal Pain Upper subjects affected / exposed occurrences (all)	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0	0 / 180 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	5 / 60 (8.33%) 5	2 / 60 (3.33%) 2	10 / 180 (5.56%) 12
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain subjects affected / exposed occurrences (all)	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0	0 / 180 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0	0 / 180 (0.00%) 0
Skin and subcutaneous tissue disorders Dermatitis Diaper subjects affected / exposed occurrences (all)	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0	11 / 180 (6.11%) 15
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	23 / 60 (38.33%) 28	24 / 60 (40.00%) 30	86 / 180 (47.78%) 138
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	4 / 60 (6.67%) 4	0 / 60 (0.00%) 0	0 / 180 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0	0 / 180 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 60 (0.00%) 0	0 / 60 (0.00%) 0	8 / 180 (4.44%) 8
Otitis Media			

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	2 / 60 (3.33%)	3 / 60 (5.00%)	15 / 180 (8.33%)
occurrences (all)	2	4	15
Viral Infection			
subjects affected / exposed	1 / 60 (1.67%)	5 / 60 (8.33%)	11 / 180 (6.11%)
occurrences (all)	1	5	11
Pharyngitis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences (all)	0	0	0
Acarodermatitis			
subjects affected / exposed	4 / 60 (6.67%)	1 / 60 (1.67%)	2 / 180 (1.11%)
occurrences (all)	4	1	2
Pyoderma			
subjects affected / exposed	3 / 60 (5.00%)	0 / 60 (0.00%)	0 / 180 (0.00%)
occurrences (all)	3	0	0
Pharyngotonsillitis			
subjects affected / exposed	2 / 60 (3.33%)	3 / 60 (5.00%)	0 / 180 (0.00%)
occurrences (all)	3	3	0
Bronchiolitis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	9 / 180 (5.00%)
occurrences (all)	0	0	10

Non-serious adverse events	Cohort 2, Group 4: 3 Doses		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	122 / 179 (68.16%)		
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	10 / 179 (5.59%)		
occurrences (all)	10		
Blood and lymphatic system disorders			

Anaemia subjects affected / exposed occurrences (all)	3 / 179 (1.68%) 3		
Gastrointestinal disorders Abdominal Pain Upper subjects affected / exposed occurrences (all)	0 / 179 (0.00%) 0		
Diarrhoea subjects affected / exposed occurrences (all)	15 / 179 (8.38%) 16		
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain subjects affected / exposed occurrences (all)	0 / 179 (0.00%) 0		
Cough subjects affected / exposed occurrences (all)	0 / 179 (0.00%) 0		
Skin and subcutaneous tissue disorders Dermatitis Diaper subjects affected / exposed occurrences (all)	18 / 179 (10.06%) 19		
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	92 / 179 (51.40%) 131		
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	0 / 179 (0.00%) 0		
Rhinitis subjects affected / exposed occurrences (all)	0 / 179 (0.00%) 0		
Conjunctivitis subjects affected / exposed occurrences (all)	7 / 179 (3.91%) 8		
Otitis Media			

subjects affected / exposed	0 / 179 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	11 / 179 (6.15%)		
occurrences (all)	11		
Viral Infection			
subjects affected / exposed	11 / 179 (6.15%)		
occurrences (all)	13		
Pharyngitis			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences (all)	0		
Acarodermatitis			
subjects affected / exposed	5 / 179 (2.79%)		
occurrences (all)	5		
Pyoderma			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences (all)	0		
Pharyngotonsillitis			
subjects affected / exposed	0 / 179 (0.00%)		
occurrences (all)	0		
Bronchiolitis			
subjects affected / exposed	7 / 179 (3.91%)		
occurrences (all)	7		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 November 2014	Amended to revise the study design as follows: <ul style="list-style-type: none">• The age stratification was modified.• The number of blood draws for Cohort 1 was reduced from 5 to 4 and for Cohort 2 was reduced from 7 to 5.• The number of formulation arms was reduced from 11 to 8 based on data from the adult trial, NOR-107.• Assessed avidity of anti-norovirus VLP antibodies by age, dose and regimen.• A licensed benefit vaccine was mentioned to be offered to all participants after trial exit.
26 March 2015	Amended to change the trial design with regard to the down selection of formulations based on additional data from the adult trial NOR-107. Specifically, the new antibody data from trial NOR-107 resulted in similar immunogenicity and safety in adults administered the trial vaccine both with and without the MPL adjuvant when combined with Al(OH) ₃ adjuvant. Therefore, the decision was made to evaluate the trial vaccine with the Al(OH) ₃ adjuvant alone in subjects enrolled in trial NOR-202. Therefore, the number of formulation arms in this study has been further reduced from eight to four.
01 March 2016	Amended to enroll an additional 120 children (1 to < 4 years; designated Group 2a) in order to assess the safety and immunogenicity of the recently manufactured NoV vaccine in a similar age group to Group 2.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported